-
1
-
-
84864285795
-
Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
-
(2012)
Diabetologia
, vol.55
, pp. 1577-1596
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
2
-
-
37349008890
-
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
-
Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-48.
-
(2007)
Clin Ther
, vol.29
, pp. 2333-2348
-
-
Barnett, A.H.1
Burger, J.2
Johns, D.3
-
3
-
-
26944477362
-
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
-
Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-69.
-
(2005)
Ann Intern Med
, vol.143
, pp. 559-569
-
-
Heine, R.J.1
van Gaal, L.F.2
Johns, D.3
-
4
-
-
34247195226
-
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study
-
Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-67.
-
(2007)
Diabetologia
, vol.50
, pp. 259-267
-
-
Nauck, M.A.1
Duran, S.2
Kim, D.3
Johns, D.4
Northrup, J.5
Festa, A.6
-
5
-
-
79951684079
-
Why observational studies should be among the tools used in comparative effectiveness research
-
Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood). 2010;10:1818-25.
-
(2010)
Health Aff (Millwood)
, vol.10
, pp. 1818-1825
-
-
Dreyer, N.A.1
Tunis, S.R.2
Berger, M.3
Ollendorf, D.4
Mattox, P.5
Gliklich, R.6
-
6
-
-
79955736485
-
Pragmatic trials-guides to better patient care?
-
Ware JH, Hamel MB. Pragmatic trials-guides to better patient care? N Engl J Med. 2011;364:1865-7.
-
(2011)
N Engl J Med
, vol.364
, pp. 1865-1867
-
-
Ware, J.H.1
Hamel, M.B.2
-
7
-
-
37749024537
-
Importance of observational studies in clinical practice
-
Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29 Spec No:1284-92.
-
(2007)
Clin Ther
, vol.29
, pp. 1284-1292
-
-
Ligthelm, R.J.1
Borzì, V.2
Gumprecht, J.3
Kawamori, R.4
Wenying, Y.5
Valensi, P.6
-
8
-
-
0037258518
-
Observational research methods. Research design II: Cohort, cross sectional, and case-control studies
-
Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20:54-60.
-
(2003)
Emerg Med J
, vol.20
, pp. 54-60
-
-
Mann, C.J.1
-
9
-
-
84863903161
-
Patients with type 2 diabetes initiating exenatide BID or insulin in clinical practice: CHOICE study
-
Matthaei S, Reaney M, Mathieu C, et al. Patients with type 2 diabetes initiating exenatide BID or insulin in clinical practice: CHOICE study. Diabetes Ther. 2012;3:6.
-
(2012)
Diabetes Ther
, vol.3
, pp. 6
-
-
Matthaei, S.1
Reaney, M.2
Mathieu, C.3
-
10
-
-
67649321802
-
Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: Baseline data from the INSTIGATE study
-
Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin. 2009;25:691-700.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 691-700
-
-
Jones, S.1
Benroubi, M.2
Castell, C.3
-
11
-
-
33845788010
-
Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies
-
Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat. 2007;17:1-13.
-
(2007)
J Biopharm Stat
, vol.17
, pp. 1-13
-
-
Yue, L.Q.1
-
12
-
-
83655184782
-
1c of >7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
-
Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of >7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14:77-82.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 77-82
-
-
Zinman, B.1
Schmidt, W.E.2
Moses, A.3
-
13
-
-
84899784383
-
TREAT Study Investigators. Costs and clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes: Results from the TREAT study
-
Lisbon, Portugal, 12-16 September
-
Benroubi M, Schmitt H, Cleall SP, et al., TREAT Study Investigators. Costs and clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes: results from the TREAT study. Poster presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal, 12-16 September 2011.
-
(2011)
Poster Presented At the 47th European Association For the Study of Diabetes (EASD) Annual Meeting
-
-
Benroubi, M.1
Schmitt, H.2
Cleall, S.P.3
-
14
-
-
0034641568
-
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
-
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
-
(2000)
BMJ
, vol.321
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.3
-
15
-
-
84862302997
-
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial
-
Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379:2270-8.
-
(2012)
Lancet
, vol.379
, pp. 2270-2278
-
-
Gallwitz, B.1
Guzman, J.2
Dotta, F.3
-
16
-
-
35548947584
-
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
-
4-T Study Group
-
Holman RR, Thorne KI, Farmer AJ, 4-T Study Group, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-30.
-
(2007)
N Engl J Med
, vol.357
, pp. 1716-1730
-
-
Holman, R.R.1
Thorne, K.I.2
Farmer, A.J.3
-
17
-
-
70350534273
-
Three-year efficacy of complex insulin regimens in type 2 diabetes
-
4-T Study Group
-
Holman RR, Farmer AJ, Davies MJ, 4-T Study Group, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736-47.
-
(2009)
N Engl J Med
, vol.361
, pp. 1736-1747
-
-
Holman, R.R.1
Farmer, A.J.2
Davies, M.J.3
-
18
-
-
18144401971
-
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
-
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-100.
-
(2005)
Diabetes Care
, vol.28
, pp. 1092-1100
-
-
Defronzo, R.A.1
Ratner, R.E.2
Han, J.3
Kim, D.D.4
Fineman, M.S.5
Baron, A.D.6
-
19
-
-
7444228521
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
-
Exenatide-113 Clinical Study Group
-
Buse JB, Henry RR, Han J, Exenatide-113 Clinical Study Group, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35.
-
(2004)
Diabetes Care
, vol.27
, pp. 2628-2635
-
-
Buse, J.B.1
Henry, R.R.2
Han, J.3
-
20
-
-
17144371646
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
-
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-91.
-
(2005)
Diabetes Care
, vol.28
, pp. 1083-1091
-
-
Kendall, D.M.1
Riddle, M.C.2
Rosenstock, J.3
-
21
-
-
81855221189
-
Exenatide BID Observational Study (ExOS): Results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting
-
Bergenstal RM, Garrison LP, Miller LA, et al. Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011;27:2335-42.
-
(2011)
Curr Med Res Opin
, vol.27
, pp. 2335-2342
-
-
Bergenstal, R.M.1
Garrison, L.P.2
Miller, L.A.3
-
22
-
-
79951668719
-
Exenatide bid observational study (ExOS): Baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting
-
Bergenstal RM, Garrison LP Jr, Wintle M, et al. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin. 2011;27:531-40.
-
(2011)
Curr Med Res Opin
, vol.27
, pp. 531-540
-
-
Bergenstal, R.M.1
Garrison Jr., L.P.2
Wintle, M.3
-
23
-
-
70450203583
-
Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
-
Brixner DI, McAdam-Marx C, Ye X, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab. 2009;11:1122-30.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 1122-1130
-
-
Brixner, D.I.1
McAdam-Marx, C.2
Ye, X.3
-
24
-
-
78449248761
-
ABCD Nationwide Exenatide Audit Contributors. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit
-
Ryder REJ, Thong KY, Cull ML, et al., ABCD Nationwide Exenatide Audit Contributors. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diab Int. 2010;27:352-7.
-
(2010)
Pract Diab Int
, vol.27
, pp. 352-357
-
-
Ryder, R.E.J.1
Thong, K.Y.2
Cull, M.L.3
-
26
-
-
84871124257
-
Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE
-
Liebl A, Jones S, Goday A, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther. 2012;3:9.
-
(2012)
Diabetes Ther
, vol.3
, pp. 9
-
-
Liebl, A.1
Jones, S.2
Goday, A.3
-
27
-
-
84873029199
-
AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: A summary of the key findings
-
Bennett WL, Balfe LM, Faysal JM. AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings. J Manag Care Pharm. 2012;18(1 Suppl. A):1-22.
-
(2012)
J Manag Care Pharm
, vol.18
, Issue.1 SUPPL. A
, pp. 1-22
-
-
Bennett, W.L.1
Balfe, L.M.2
Faysal, J.M.3
-
28
-
-
69949117621
-
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): A randomised controlled trial
-
Liraglutide effect and action in Diabetes 5 (LEAD-5) met + SU Study Group
-
Russell-Jones D, Vaag A, Schmitz O, Liraglutide effect and action in Diabetes 5 (LEAD-5) met + SU Study Group, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046-55.
-
(2009)
Diabetologia
, vol.52
, pp. 2046-2055
-
-
Russell-Jones, D.1
Vaag, A.2
Schmitz, O.3
-
29
-
-
77953859640
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial
-
Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234-43.
-
(2010)
Lancet
, vol.375
, pp. 2234-2243
-
-
Diamant, M.1
van Gaal, L.2
Stranks, S.3
-
30
-
-
84886943101
-
Newer agents for blood glucose control in type 2 diabetes: Systematic review and economic evaluation
-
Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1-248.
-
(2010)
Health Technol Assess
, vol.14
, pp. 1-248
-
-
Waugh, N.1
Cummins, E.2
Royle, P.3
-
31
-
-
84862698727
-
Post-marketing studies of new insulins: Sales or science?
-
Gale EA. Post-marketing studies of new insulins: sales or science? BMJ. 2012;344:e3974.
-
(2012)
BMJ
, vol.344
-
-
Gale, E.A.1
-
32
-
-
84862689505
-
Post-marketing observational trials and catastrophic health expenditure
-
Yudkin JS. Post-marketing observational trials and catastrophic health expenditure. BMJ. 2012;344: e3987.
-
(2012)
BMJ
, vol.344
-
-
Yudkin, J.S.1
-
33
-
-
84876893139
-
-
press release). San Diego, CA: Amylin Pharmaceuticals, Inc. c2012 (updated March 23, 2012; cited June 13, Accessed 12 Dec 2012
-
Byetta approved for use with basal insulin in Europe (press release). San Diego, CA: Amylin Pharmaceuticals, Inc. c2012 (updated March 23, 2012; cited June 13, 2012). https://investor.lilly.com/releasedetail2.cfm?ReleaseID=659089. Accessed 12 Dec 2012.
-
(2012)
Byetta Approved For Use With Basal Insulin In Europe
-
-
-
34
-
-
84899864631
-
ABCD Nationwide Exenatide and Liraglutide Audit Contributors. ABCD Nationwide Exenatide and Liraglutide Audits
-
London, 30 March-1 April
-
Ryder RJ, Thong K, ABCD Nationwide Exenatide and Liraglutide Audit Contributors. ABCD Nationwide Exenatide and Liraglutide Audits. Oral presentation at the diabetes UK annual professional conference, London, 30 March-1 April 2011
-
(2011)
Oral Presentation At the Diabetes UK Annual Professional Conference
-
-
Ryder, R.J.1
Thong, K.2
|